Markets
Tech
Media
Success
Video
Markets
Premarkets
Dow
After-Hours
Market Movers
Fear & Greed
World Markets
Investing
Markets Now
Before the Bell
Leading Indicator
Global Energy Challenge
Economy
Energy
Tech
Innovate
Gadget
Mission: Ahead
Upstarts
Business Evolved
Work Transformed
Innovative Cities
Unhackable
Media
Reliable Sources
Success
Boss Files
Fresh Money
Cars
Homes
Biz + Leisure
Center Piece
Perspectives
Video
International
Switzerland
India
Davos
Passion to Portfolio
On: Germany
More
Newsletters
About Us
Accessibility and CC
U.S.
World
Politics
Business
Opinion
Health
Entertainment
Tech
Style
Travel
Sports
Video
Shop
VR
More...
Follow CNN Business
Do Not Sell
Novo Nordisk A/S
(NYSE:NVO)
147.25
Delayed Data
As of Mar 21
-0.04
/
-0.03%
Today’s Change
95.02
Today
|||
52-Week Range
147.42
+8.80%
Year-to-Date
Quote
Profile
News
Charts
Forecasts
Financials
Shareholders
Competitors
Latest NVO News
|
Press Releases
Gilead (GILD) Exercises Option to License Nurix's Candidate
Mar 21 / Zacks.com - Paid Partner Content
Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants
Mar 15 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights Credit Suisse, Meta Platforms, Novo Nordisk and Salesforce
Mar 21 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75%
Mar 15 / Zacks.com - Paid Partner Content
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Mar 21 / Zacks.com - Paid Partner Content
AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?
Mar 15 / Zacks.com - Paid Partner Content
Universal Health (UHS) Up 26% in 6 Months: More Room to Run?
Mar 20 / Zacks.com - Paid Partner Content
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
Mar 14 / Zacks.com - Paid Partner Content
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II
Mar 20 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Dips More Than Broader Markets: What You Should Know
Mar 13 / Zacks.com - Paid Partner Content
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
Mar 20 / Zacks.com - Paid Partner Content
Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret
Mar 13 / Zacks.com - Paid Partner Content
Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion
Mar 17 / Zacks.com - Paid Partner Content
Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee
Mar 10 / Zacks.com - Paid Partner Content
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote
Mar 17 / Zacks.com - Paid Partner Content
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Mar 10 / Zacks.com - Paid Partner Content
2 Top Healthcare Stocks to Buy for the Long Haul
Mar 17 / MotleyFool.com - Paid Partner Content
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
Mar 10 / Zacks.com - Paid Partner Content
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%
Mar 17 / Zacks.com - Paid Partner Content
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
Mar 10 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates
Mar 17 / Zacks.com - Paid Partner Content
Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study
Mar 09 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know
Mar 16 / Zacks.com - Paid Partner Content
5 Large Drug Stocks to Watch as Sector Picks Up in 2023
Mar 09 / Zacks.com - Paid Partner Content
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?
Mar 16 / Zacks.com - Paid Partner Content